



9 163
+ 9
182

<p>01/PTO Rev. 10/95</p> <p>TRANSMITTAL FORM</p> <p><i>(to be used for all correspondence during pendency of filed application)</i></p>	U.S. Department of Commerce Patent and Trademark Office	Application Number	09/067,638
	Filing Date	April 28, 1998	
	First Named Inventor	Lex M. Cowser	
	Group Art Unit Number	1631	
	Examiner Name	Ardin H. Marschel	
Total Number of Pages in This Submission	8*	Attorney Docket Number	23546-08263\ISIS2960

ENCLOSURES *(check all that apply)*

<input checked="" type="checkbox"/> Fee Transmittal Form (in duplicate) <input checked="" type="checkbox"/> Check Enclosed	<input type="checkbox"/> Issue Fee Transmittal
<input checked="" type="checkbox"/> Return Receipt Postcard	<input type="checkbox"/> Letter to Chief Draftsperson
<input type="checkbox"/> Response to Notice to File Missing Parts	<input type="checkbox"/> Formal Drawing(s): [] Sheet(s) of Figure(s) []
<input type="checkbox"/> Assignment & Recordation Cover Sheet	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Declaration	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input type="checkbox"/> Power of Attorney	<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Application Data Sheet	<input type="checkbox"/>
<input checked="" type="checkbox"/> Information Disclosure Statement & PTO/SB/08A <input checked="" type="checkbox"/> Copies of IDS Cited References	<input type="checkbox"/>
<input type="checkbox"/> After Allowance Communication to Group	<input type="checkbox"/>
<input type="checkbox"/> Request for Correction of Recorded Assignment	<input type="checkbox"/>
<input type="checkbox"/> Amendment/Response: [] Page(s) <input type="checkbox"/> After Final	<input type="checkbox"/>
<input type="checkbox"/> Status Request	<input type="checkbox"/>
<input type="checkbox"/> Revocation and Substitute Power of Attorney	<input type="checkbox"/>

REMARKS: *Number of pages does not include cited references

SIGNATURE OF ATTORNEY OR AGENT

Signature:  Attorney/Reg. No.: Narinder S. Banait, Reg. No.: 43,482 Dated: June 1, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including the enclosures identified above, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. If the Express Mail Mailing Number is filled in below, then this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service pursuant to 37 CFR 1.10.

Signature:			
Typed or Printed Name:	Narinder S. Banait	Dated:	June 1/2024.
Express Mail Mailing Number (optional):			



JUN 03 2004

FEET TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT **(\$)** 180.00

Complete if Known	
Application Number	09/067,638
Filing Date	April 28, 1998
First Named Inventor	Lex M. Cowser
Examiner Name	Ardin H. Marschel
Art Unit	1631
Attorney Docket No.	23546-08263\ISIS2960

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None
 Deposit Account:

Deposit Account Number **19-2555**

Deposit Account Name **Fenwick & West LLP**

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge all required fee(s) or any underpayment of fee(s) due under 37 CFR §1.16 or §1.17 during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee	Fee	Fee	Fee	Fee Description	Fee Paid
Code	(\$)	Code	(\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)		(\$)	-0-		

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	<input type="checkbox"/> -20** = <input type="checkbox"/>	X <input type="checkbox"/> = <input type="checkbox"/>	
Independent Claims	<input type="checkbox"/> -3** = <input type="checkbox"/>	X <input type="checkbox"/> = <input type="checkbox"/>	
Multiple Dependent			

Large Entity	Small Entity	Fee	Fee	Fee	Fee	Fee Description
Code	(\$)	Code	(\$)			
1202	18	2202	9	Claims in excess of 20		
1201	86	2201	43	Independent claims in excess of 3		
1203	290	2203	145	Multiple dependent claim, if not paid		
1204	86	2204	43	**Reissue independent claims over original patent		
1205	18	2205	9	**Reissue claims in excess of 20 and over original patent		
SUBTOTAL (2)		(\$)	-0-			

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid		
Fee Code	Fee (\$)	Fee Code (\$)			
1051	130	2051	65 Surcharge - late filing fee or oath		
1052	50	2052	25 Surcharge - late provisional filing fee or cover sheet		
1053	130	1053	130 Non-English specification		
1812	2,520	1812	2,520 For filing a request for ex parte reexamination		
1804	920*	1804	920* Requesting publication of SIR prior to Examiner action		
1805	1,840*	1805	1,840* Requesting publication of SIR after Examiner action		
1251	110	2251	55 Extension for reply within first month		
1252	420	2252	210 Extension for reply within second month		
1253	950	2253	475 Extension for reply within third month		
1254	1,480	2254	740 Extension for reply within fourth month		
1255	2,010	2255	1,005 Extension for reply within fifth month		
1401	330	2401	165 Notice of Appeal		
1402	330	2402	165 Filing a brief in support of an appeal		
1403	290	2403	145 Request for oral hearing		
1451	1,510	1451	1,510 Petition to institute a public use proceeding		
1452	110	2452	55 Petition to revive - unavoidable		
1453	1,330	2453	665 Petition to revive - unintentional		
1501	1,330	2501	665 Utility issue fee (or reissue)		
1502	480	2502	240 Design issue fee		
1503	640	2503	320 Plant issue fee		
1460	130	1460	130 Petitions to the Commissioner		
1807	50	1807	50 Processing fee under 37 CFR 1.17(g)		
1806	180	1806	180 Submission of Information Disclosure Stmt		
8021	40	8021	40 Recording each patent assignment per property (times number of properties)		
1809	770	2809	385 Filing a submission after final rejection (37 CFR 1.129(a))		
1810	770	2810	385 For each additional invention to be examined (37 CFR 1.129(b))		
1801	770	2801	385 Request for Continued Examination (RCE)		
1802	900	1802	900 Request for expedited examination of a design application		
Other fee (specify) _____					
SUBTOTAL (2)		(\$)	0-		
		SUBTOTAL (3)		(\$)	180.00

*Reduced by Basic Filing Fee Paid

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Narinder S. Banait	Registration No. (Attorney/Agent)	43,482	Telephone (650) 335-7818
Signature		Date	June 1/2004	



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Lex M. Cowsert et al.
APPLICATION NO.: 09/067,638
FILING DATE: April 28, 1998
TITLE: System of Components for Preparing Oligonucleotides
EXAMINER: Ardin H. Marschel
GROUP ART UNIT: 1631
ATTY. DKT. NO.: 23546-08263\ISIS2960

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Dated: June 1/2004

By: Narinder S. Banait
Narinder S. Banait, Reg. No.: 43,482

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner. Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

- within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred;
- before the mailing of a first official action after the filing of a request for continued examination (RCE) under 37 CFR § 1.114;

- after three months of the filing date of this national application or the date of entry of the national stage in an international application, or after the mailing date of the first official action on the merits, whichever event last occurred, but before the mailing date of the first to occur of either: (1) a final action under 37 CFR §1.113; or (2) an action that otherwise closes prosecution in the application, and:
 - attached hereto is the fee set forth under 37 CFR §1.17(p) for submission of this Information Disclosure Statement under 37 CFR. § 1.97(c); OR
 - Applicant certifies pursuant to 37 CFR § 1.97(e) that:
 - each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; OR
 - no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 CFR § 1.56(c) more than three months prior to the filing of this Statement;
 - on or before the payment of the issue fee but after the mailing date of the first to occur of either: (1) a final action under 37 CFR § 1.113; (2) a notice of allowance under 37 CFR § 1.311; or (3) an action that otherwise closes prosecution in the application, and:
 - Applicant certifies pursuant to 37 CFR. § 1.97(e) that:
 - each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; or
 - no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this

certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 CFR § 1.56(c) more than three months prior to the filing of this Statement; AND


- attached hereto is the fee set forth under 37 CFR §1.17(p) for submission of this Information Disclosure Statement under 37 CFR. § 1.97(c); OR
- after the payment of the issue fee. Applicant requests that the information contained in this Information Disclosure Statement be placed in the file according to 37 CFR § 1.97(i), although the information may not be considered by the USPTO.
- This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. _____, filed on _____, and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 CFR § 1.98(d).
- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 CFR § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement. 37 CFR § 1.704(d).
- Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted,
LEX M. COWSERT ET AL.

Dated: June 1/2004

By: Narinder S. Banait, Ph.D.
Narinder S. Banait, Ph.D.
Registration No. 43,482
Attorney for Applicants
Fenwick & West LLP
801 California Street
Mountain View, CA 94041
Telephone: 650-335-7818
Facsimile: 650-938-5200
E-mail: nbanait@fenwick.com



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 1 of 1 Attorney Docket Number 23546-08263\ISIS2960

Complete if Known

Application No.	09/067,638
Filing Date	April 28, 1998
First Named Inventor	Lex M. Cowser
Art Unit	1631
Examiner Name	Ardin H. Marschel

U.S. PATENT DOCUMENTS				
		Document No.		
Examiner Initials*	Cite No. ¹	Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS				
		Foreign Patent Document		
Examiner Initials*	Cite No. ¹	Country Code ³ – Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
				T ⁶

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
		MITSUHASHI, MASATO, Strategy for Designing Specific Antisense Oligonucleotide Sequences, J Gastroenterol 1997, 32:pgs. 282-287		
		HYNDMAN, D. ET AL., Software to Determine Optimal Oligonucleotide Sequences Based on Hybridization Simulation Data, BioTechniques 20: pgs. 1090-1097		
		STULL, ROBERT A. ET AL., Predicting Antisense Oligonucleotide Inhibitory Efficacy: a computational approach using histograms and thermodynamic indices, Nucleic Acids Research, Vol. 20, No. 13, pgs. 3501-3508		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.